Auxilium's Xiaflex shows positive Phase 4 results Auxilium announced interim data from its Phase 4 retreatment study evaluating Xiaflex in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord. Xiaflexis a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord, and has been granted Orphan Drug Designation in the U.S. by the FDA. 87% of recurrent contractures of metacarpophalangeal joints were successfully retreated. Patients showed an average 83% improvement in fixed flexion. 85% of recurrent contractures of proximal interphalangeal were successfully retreated. Retreatment with CCH was well tolerated.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.